Gulf International Bank UK Ltd Raises Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Gulf International Bank UK Ltd increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 19.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 9,834 shares of the medical research company’s stock after acquiring an additional 1,589 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Charles River Laboratories International were worth $4,058,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Assetmark Inc. raised its holdings in shares of Charles River Laboratories International by 644.4% during the second quarter. Assetmark Inc. now owns 67 shares of the medical research company’s stock worth $25,000 after purchasing an additional 58 shares during the last quarter. AdvisorNet Financial Inc purchased a new position in shares of Charles River Laboratories International during the third quarter worth $26,000. Wolff Wiese Magana LLC raised its holdings in shares of Charles River Laboratories International by 119.1% during the third quarter. Wolff Wiese Magana LLC now owns 103 shares of the medical research company’s stock worth $42,000 after purchasing an additional 56 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in Charles River Laboratories International by 314.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 145 shares of the medical research company’s stock valued at $54,000 after buying an additional 110 shares in the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new position in Charles River Laboratories International in the second quarter valued at $54,000. 91.64% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have weighed in on CRL. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $480.00 to $465.00 and set an “overweight” rating for the company in a report on Thursday, November 4th. Citigroup cut their price objective on shares of Charles River Laboratories International from $425.00 to $400.00 and set a “neutral” rating for the company in a report on Thursday, November 4th. Robert W. Baird reaffirmed a “buy” rating on shares of Charles River Laboratories International in a report on Monday, December 20th. Evercore ISI reissued a “buy” rating on shares of Charles River Laboratories International in a research note on Thursday, October 14th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Charles River Laboratories International from $354.00 to $409.00 and gave the stock a “buy” rating in a research note on Tuesday, November 16th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $415.50.

NYSE:CRL opened at $355.01 on Friday. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.40 and a quick ratio of 1.22. The firm has a market capitalization of $17.91 billion, a price-to-earnings ratio of 45.87, a PEG ratio of 2.16 and a beta of 1.17. The company’s 50-day moving average is $366.58 and its two-hundred day moving average is $397.38. Charles River Laboratories International, Inc. has a 1-year low of $249.48 and a 1-year high of $460.21.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Tuesday, November 2nd. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.58 by $0.12. The company had revenue of $895.90 million for the quarter, compared to analyst estimates of $902.03 million. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 23.14%. Charles River Laboratories International’s revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.33 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.25 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

Further Reading: Does the discount rate affect the economy?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.